Research & Development

We are actively driving research and development globally with partnerships specializing in the fields of interest. Our focus is to develop botanical based pharmaceutical medicine for in-market use globally

Psilocybin

• Phase 2b Clinical Trial application submitted in South Africa for the use of Psilocybin API for the treatment of Major Depressive Disorder
• Psilocybin cultivation research and development application submitted in South Africa on current 23 hectare property

Cannabidiol (CBD) for the treatment of Traumatic Brain Injury

Cannabidiol (CBD) for the treatment of Traumatic Brain Injury

• Utilizing CBD API for the treatment of TBI in sports related head injuries
• Phase 1 Clinical Trial submission expected Q1 2022 with commencement late 2022

Cannabidiol (CBD) for the treatment Schizophrenia

• Utilizing CBD API in combination with other treatments in the reduction of relapse schizophrenia
• Phase 1 Clinical Trial submission expected Q1 2022 with commencement second half 2022

Cannabinoid combination with Turmeric

• Clinical Trial for safety and efficacy Q2 2022 – for use as a supplement, aiding in the reduction of inflammation in joints, muscles and tissues for use in our everyday lives

CBD Suppository

• Vaginal suppository for the treatment and prevention of BV and PMS symptoms such as cramping and pain
• In product development stage with preclinical trial planned for Q3 2021

Scroll to Top